Home » Stocks » BIOC

Biocept, Inc. (BIOC)

Stock Price: $6.03 USD -0.21 (-3.37%)
Updated Feb 26, 2021 4:00 PM EST - Market closed
After-hours: $5.90 -0.13 (-2.16%) Feb 26, 7:10 PM
Market Cap 80.78M
Revenue (ttm) 10.73M
Net Income (ttm) -25.45M
Shares Out 11.32M
EPS (ttm) -2.37
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $6.03
Previous Close $6.24
Change ($) -0.21
Change (%) -3.37%
Day's Open 6.26
Day's Range 5.64 - 6.39
Day's Volume 329,838
52-Week Range 2.11 - 13.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Benzinga - 4 days ago

Biocept Inc (NASDAQ: BIOC) will collaborate with Protean BioDiagnostics Inc to research Biocept's Target Selector molecular assay's ability to determine EGFR status in non-small cell lung canc...

Proactive Investors - 5 days ago

Biocept Inc (NASDAQ:BIOC) announced plans Tuesday to collaborate with Protean BioDiagnostics Inc to research the ability of its own Target Selector molecular assays to determine the status of ...

Business Wire - 5 days ago

SAN DIEGO--(BUSINESS WIRE)--Biocept and Protean BioDiagnostics Collaborate to Demonstrate Advantages of Biocept's Target Selector Assay for Non-Small Cell Lung Cancer Patients.

Proactive Investors - 1 week ago

Biocept Inc (NASDAQ:BIOC) announced Tuesday that its Target Selector molecular assay kit detected mutations in up to 50% of tissue biopsy specimens from non-small cell lung cancer patients tha...

Business Wire - 1 week ago

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, will present data showing that its Target Selector™ molecula...

Business Wire - 3 weeks ago

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services for physicians treating patients with cancer, provides an upd...

Business Wire - 3 weeks ago

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically act...

Business Wire - 1 month ago

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular testing to provide physicians with clinically actionable information to improve patient out...

PRNewsWire - 1 month ago

SAN DIEGO, Jan. 4, 2021 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with cl...

PRNewsWire - 1 month ago

SAN DIEGO, Dec. 31, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with c...

PRNewsWire - 1 month ago

SAN DIEGO, Dec. 30, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with c...

PRNewsWire - 3 months ago

SAN DIEGO, Nov. 20, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with c...

Seeking Alpha - 3 months ago

Biocept, Inc. (BIOC) CEO Michael Nall on Q3 2020 Results - Earnings Call Transcript

PRNewsWire - 3 months ago

SAN DIEGO, Nov. 12, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with c...

PRNewsWire - 3 months ago

SAN DIEGO, Nov. 12, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services for physicians treating patients with cancer, an...

PRNewsWire - 3 months ago

SAN DIEGO, Nov. 9, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with cl...

PRNewsWire - 3 months ago

SAN DIEGO, Nov. 5, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests, products and services designed to provide physicians with cli...

PRNewsWire - 3 months ago

SAN DIEGO, Oct. 29, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services for physicians treating patients with cancer, an...

PRNewsWire - 5 months ago

SAN DIEGO, Sept. 4, 2020 /PRNewswire/ -- Biocept, Inc.

PRNewsWire - 5 months ago

SAN DIEGO, Aug. 31, 2020 /PRNewswire/ -- Biocept, Inc.

GlobeNewsWire - 6 months ago

SAN DIEGO, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable info...

GlobeNewsWire - 6 months ago

SAN DIEGO, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable in...

GlobeNewsWire - 6 months ago

SAN DIEGO, Aug. 19, 2020 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable i...

Seeking Alpha - 6 months ago

Biocept, Inc. (BIOC) CEO Michael Nall on Q2 2020 Results - Earnings Call Transcript

PRNewsWire - 6 months ago

SAN DIEGO, Aug. 12, 2020 /PRNewswire/ -- Biocept, Inc.

Zacks Investment Research - 6 months ago

Biocept (BIOC) is expected to have suffered in Q2 from reduced oncology practices and postponement of patient appointments.

PRNewsWire - 6 months ago

SAN DIEGO, Aug. 6, 2020 /PRNewswire/ -- Biocept, Inc.

PRNewsWire - 6 months ago

SAN DIEGO, Aug. 3, 2020 /PRNewswire/ -- Biocept, Inc.

InvestorPlace - 6 months ago

These seven penny stocks have the right catalysts, business models, and tailwinds. Read about why the risk is worth it.

Other stocks mentioned: AMPE, BOXL, EMAN
PRNewsWire - 7 months ago

SAN DIEGO, July 16, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable informa...

PRNewsWire - 7 months ago

SAN DIEGO, June 30, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable informa...

PRNewsWire - 8 months ago

SAN DIEGO, June 24, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable informa...

PRNewsWire - 8 months ago

SAN DIEGO, June 22, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable informa...

PRNewsWire - 8 months ago

SAN DIEGO, June 5, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable informat...

PRNewsWire - 9 months ago

SAN DIEGO, May 20, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable informat...

PRNewsWire - 9 months ago

SAN DIEGO, May 14, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable informat...

Seeking Alpha - 9 months ago

Biocept, Inc. (BIOC) CEO Michael Nall on Q1 2020 Results - Earnings Call Transcript

Benzinga - 10 months ago

As the COVID-19 pandemic continues to ravage the globe, having claimed over 115,000 lives, health care companies have are pursuing diagnostics tests, potential vaccines and therapies.

Other stocks mentioned: ATHX, BCRX, CANF
Seeking Alpha - 11 months ago

Biocept, Inc. (BIOC) CEO Michael Nall on Q4 2019 Results - Earnings Call Transcript

Market Watch - 11 months ago

Shares of Biocept Inc. BIOC, -42.27% plummeted 42% on very heavy volume in morning trading Monday, after the provider of liquid cancer tests announced the pricing of stock offering at a deep d...

Seeking Alpha - 1 year ago

Speculative Spotlight: Biocept Is Undervalued Despite Commercial Progress

Seeking Alpha - 1 year ago

Biocept, Inc. (BIOC) CEO Michael Nall on Q3 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Biocept, Inc. (BIOC) CEO Michael Nall on Q2 2019 Results - Earnings Call Transcript

Market Watch - 1 year ago

Shares of Biocept Inc. BIOC, +84.16% soared 86% on very heavy volume Monday, after the provider of liquid biopsy tests announced the commercial launch of Target Selector NGS Lung Panel, the li...

Benzinga - 1 year ago

Shares of Biocept Inc (NASDAQ: BIOC), a molecular diagnostics company specializing in biomarker analysis of circulating tumor-associated DNA, are making a strong upward move Monday.

Seeking Alpha - 1 year ago

Biocept, Inc. (BIOC) CEO Michael Nall on Q1 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Biocept, Inc. (BIOC) CEO Michael Nall on Q4 2018 Results - Earnings Call Transcript

About BIOC

Biocept, an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. It offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, smal... [Read more...]

Industry
Diagnostics & Research
IPO Date
Feb 5, 2014
CEO
Michael Nall
Employees
88
Stock Exchange
NASDAQ
Ticker Symbol
BIOC
Full Company Profile

Financial Performance

In 2019, Biocept's revenue was $5.53 million, an increase of 70.09% compared to the previous year's $3.25 million. Losses were -$25.14 million, 2.31% more than in 2018.

Financial Statements

Analyst Forecasts

According to one analyst, the rating for Biocept stock is "Buy" and the 12-month stock price forecast is 20.00.

Price Target
$20.00
Analyst Consensus: Buy